The Hemoglobinopathies Market is expected to increase at a CAGR of 10.37 percent, from USD 6.75 billion in 2020 to USD 14.86 billion in 2027.

Sickle cell disease, alpha thalassemia, and beta thalassemia are the most common hemoglobinopathies. In terms of value, the global hemoglobinopathy market is estimated to grow at a CAGR of 8.3% over the forecast period, reaching a market valuation of US$...